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PObesity and CV Mortality in ESRD
Abdominal Obesity and All-Cause and
Cardiovascular Mortality in End-Stage Renal Disease
Maurizio Postorino, MD, Carmen Marino, TECH, Giovanni Tripepi, DRSTAT, Carmine Zoccali, PROF, on
behalf of the CREDIT (Calabria Registry of Dialysis and Transplantation) Working Group
Reggio Calabria, Italy
Objective The aim of this study was to investigate the predictive value for all-cause and cardiovascular (CV) death of an-
thropometric measurements of abdominal obesity in patients with end-stage renal disease (ESRD).
Background Surrogate measures of abdominal obesity and segmental fat distribution (waist circumference and waist/hip
ratio [WHR]) are stronger predictors of all-cause and CV death than body mass index (BMI) in the general popu-
lation, but the issue has never been investigated in patients with ESRD.
Methods We performed a prospective cohort study in 537 patients with ESRD (age 63  15 years).
Results In BMI-adjusted Cox models, waist circumference was a direct predictor of all-cause and CV mortality (p 
0.001), whereas BMI showed an inverse relationship (p  0.001) with these outcomes. The incidence rates of
overall and CV death were maximal in patients with relatively lower BMI scores (below the median) and higher
waist circumferences (at least the median) and minimal in patients with higher BMI scores (at least the median)
and small waist circumferences (below the median). The prognostic power of waist circumference for all-cause
(hazard ratio [HR] [10-cm increase]: 1.23; 95% confidence interval [CI]: 1.02 to 1.47; p  0.03) and CV
mortality (HR: 1.37; 95% CI: 1.09 to 1.73; p  0.006) remained significant after adjustment for CV comor-
bidities and traditional and emerging risk factors. WHR was found to be related to all-cause (p  0.009)
and CV mortality (p  0.07).
Conclusions Abdominal obesity underlies a high risk of all-cause and CV mortality in patients with ESRD. Redefinition of
nutritional status by combining the metrics of abdominal obesity and BMI may refine prognosis in the ESRD
population. (J Am Coll Cardiol 2009;53:1265–72) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.040h
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sbesity has reached epidemic proportions worldwide. Tem-
oral trends in increasing obesity in the dialysis population
re of the same magnitude as those in the general popula-
ion, and the prevalence of this disease in the U.S. Renal
ata System was more than 25% in 2002 (1). Body mass
ndex (BMI) (i.e., body weight scaled to height) is the most
idely used anthropometric measure of overall body size in
pidemiology research, and this metric has been formally
ecommended for nutritional status assessment and moni-
oring in end-stage renal disease (ESRD) (2,3). Studies in
ialysis registries (4,5) and large medical databases (6–8)
nd worldwide extended observational studies (9) have
oherently shown that BMI is inversely associated with
ortality. This phenomenon is not specific to ESRD
ecause it is also common in other chronic diseases such as
rom the Nephrology, Dialysis and Transplantation Unit and CNR-IBIM Clinical
pidemiology and Pathophysiology of Renal Diseases and Hypertension, Reggio
alabria, Italy. This study was supported by grants from the Consiglio Nazionale
elle Ricerche and Regione Calabria, Italy.t
Manuscript received September 16, 2008; revised manuscript received December 5,
008, accepted December 8, 2008.eart failure (10) and coronary heart disease (11), and recent
bservations indicate that the association of this metric with
urvival in ESRD does not deviate from that observed in the
ackground general population (12). However, a high BMI
hould not be seen as a protective factor because “obese
arcopenia” (i.e., high body mass accompanying low urinary
reatinine [13]), or protein energy malnutrition (14), un-
erlies a high death risk in patients with ESRD. BMI apart,
nthropometric measures of abdominal obesity and body fat
istribution like waist circumference and waist/hip ratio
WHR) appear directly, rather than inversely, associated
ith all-cause and cardiovascular (CV) mortality in the
eneral population. In this respect, WHR emerged as the
trongest body size measure associated with myocardial
nfarction in a worldwide extended case-control study (IN-
ERHEART) (15). Importantly, in the INTERHEART
tudy, BMI had no predictive power for myocardial infarc-
ion in an analysis adjusting for WHR and other risk
actors, whereas the predictive power of WHR became
tronger after extensive statistical adjustment, suggesting
hat visceral fat is a body component that contributes
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tion in the general population.
However, it was emphasized
that it remains largely unknown
whether metrics of waist circum-
ference hold prognostic value for
death and CV complications in
patients with chronic diseases
(16). Recent analyses of the sub-
cohort of individuals with mild
to moderate chronic kidney dis-
ease (CKD) in 2 community-
ased studies in the elderly indicated that WHR holds
redictive power for CV events also in the early stages of
KD (17). Notwithstanding that ESRD is a chronic
ondition in which nutritional disorders are exceedingly
ommon (18), to date there is no study testing the value
f these indicators in this population. Also in light of the
ise of overweight and obesity in the ESRD population
19,20) and the controversial interpretation of the effect
f obesity on clinical outcomes in ESRD (2,3), the issue
f simultaneously testing the prognostic value of metrics
f overall body size (BMI) and segmental fat accumula-
ion (waist circumference and WHR) in patients with
SRD appears of particular relevance. With this back-
round in mind, we performed a cohort study aimed at
esting the predictive power for all-cause and CV death
f waist circumference and WHR.
ethods
he protocol conformed with the ethical guidelines of our
nstitution; because we used standard, anonymous registry
ata, no written informed consent was required from
articipants.
tudy population. This study was based on the dialysis
egistry of a southern Italian region (CREDIT [Calabria
egistry of Dialysis and Transplantation]) affiliated with the
talian and the European Renal Association–European
ialysis and Transplant Association Registries. The
REDIT registry includes anonymous data of all patients
ith ESRD treated in 36 dialysis units of the same region.
ollected data are those requested by national and Euro-
ean registries and additional data on comorbidities and
ther data driven by specific research projects of the regional
egistry. Twenty-four centers (67%) participated in this
tudy, and 537 patients were enrolled in this study.
tudy design and baseline data collection. Demographic,
linical, and anthropometric data of all patients treated
ith extracorporeal dialysis in participating centers were
btained between June and December 2003. For the
urpose of this study, anthropometric data (height,
eight, and waist and hip measurements) were collected
n participating centers. Waist and hip circumferences
ere measured with a nonstretchable standard tape mea-
Abbreviations
and Acronyms
BMI  body mass index
CKD  chronic kidney
disease
CRP  C-reactive protein
CV  cardiovascular
ESRD  end-stage renal
disease
WHR  waist/hip ratioure. Waist circumference was measured over the unclothed Cbdomen at the midpoint of the lower thoracic cage and
liac crest in the midaxillary line, and hip circumference was
easured at the level of the widest diameter around the
uttocks, as recommended by the World Health Organiza-
ion (21). Both weight and height were measured with
tandardized protocols. BMI vas calculated as weight in kg
ivided by height in m2. Serum C-reactive protein (CRP)
as measured by a high-sensitivity immunoturbidimetric
ethod (Dade Behring, Marburg, Germany) in a central
aboratory. Serum lipids, glucose, calcium, and phosphate
ere measured by standard methods in hospital laboratories
f participant centers. Pre-dialysis arterial pressures and
eart rates were measured 3 times after 10-min resting
eriods while the patients were seated, and the average value
f these measurements was considered in the statistical
nalysis. All measurements were obtained midweek before
ialysis.
ollow-up. All patients were followed until December
006 or censoring (study end, kidney transplantation, or lost
o observation). Primary kidney disease and causes of death
ere classified according to the coding system of the
uropean Renal Association–European Dialysis and Trans-
lantation Association (22).
tatistical analysis. Data are reported as mean  SD,
edian (interquartile range), or percent frequency, as ap-
ropriate. The association between paired variables was
ested by Pearson product moment correlation coefficient (r)
nd p value.
The prognostic value for all-cause and CV mortality of
ndicators of body size was investigated by unadjusted
nd multiple Cox regression analyses. In a first step, the
redictive value of waist and hip circumferences and their
atio was tested in bivariate Cox models adjusted for
MI. In multiple Cox regression analyses, we considered
raditional risk factors (age, sex, smoking, diabetes,
ystolic pressure, cholesterol, and triglycerides), factors
pecific to ESRD (dialysis vintage, hemoglobin, and
alcium  phosphate product), CV comorbidities, and
erum CRP level. Starting with these variables, signifi-
ant, independent predictors of all-cause and CV mor-
ality were identified by a reverse stepwise approach (p 
.10). In these analyses, we also tested the multiplicative
nteraction (23) between waist circumference, BMI, and
HR and sex and all independent predictors of all-cause
nd CV death. The 95% confidence intervals (CIs) of the
rude incidence rate of all-cause and CV mortality were
alculated as suggested by Haenszel et al. (24). Data are
xpressed as hazard ratios (HRs) and their 95% CIs that
ere calculated with the use of estimated regression coeffi-
ients and their standard errors in the Cox regression
nalysis.
All calculations were done using a standard statistical
ackage (SPSS for Windows, version 9.0.1, SPSS Inc.,
hicago, Illinois).
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he study cohort (n 537) was similar to the contemporary
ialysis population (n  1,143) for age (63 years vs. 62
ears), male sex (58% vs. 57%), diabetes (16% vs. 19%),
lood pressure (137  22/75  12 mm Hg vs. 139 
0/78  11 mm Hg), causes of renal disease, and background
omorbidities.
nthropometric measurements. Clinical, biochemical,
emodynamic, and somatometric data are summarized in
able 1. Waist circumference was higher than the sex-
pecific reference value (men 102 cm; women 88 cm) in
12 of 537 patients (39%). Hip circumference was on
verage 99.7  11.4 cm. WHR (average 0.93  0.09)
xceeded the upper limit of normal (men 0.97; women
0.85) in the majority of patients (301 of 537 [56%]), and
he proportions of patients with wider waist circumferences
nd WHR were higher in women than in men (p  0.001).
aist and hip circumferences were directly and significantly
elated to BMI (Fig. 1). BMI was normal (22.6 to 25.0
g/m2) in 139 patients. Twenty-one patients were frankly
alnourished (BMI 18.5 kg/m2), and 127 were under-
eight (BMI 18.5 to 22.5 kg/m2). One hundred and
ighty-six were overweight (BMI 25.1 to 30.0 kg/m2) and
4 were obese (BMI 30 kg/m2).
ain Clinical, Hemodynamic, and Biochemical Characteristics of th
Table 1 Main Clinical, Hemodynamic, and Biochemical Charact
Whole Cohort
Age, yrs 63 15
Dialysis vintage, months (range) 48 (19–97)
Smokers 62 (11)
Patients with diabetes 86 (16)
Patients with cardiovascular comorbidities 145 (27)
Body mass index, kg/m2 25.1 4.5
Waist/hip ratio 0.93 0.10
Waist circumference, cm 93.0 13.3
Hip circumference, cm 99.7 11.4
Systolic pressure, mm Hg 137 22
Diastolic pressure, mm Hg 75 12
Pulse pressure, mm Hg 62 17
Heart rate, beats/min 75 15
Cholesterol, mg/dl 158 44
Triglycerides, mg/dl 140 (91–215)
Calcium  phosphate, mg2/dl2 45 20
Hemoglobin, g/dl 11 2
Glucose, mmol/l 5.8 2.7
C-reactive protein, mg/l 4.7 (2.0–11.7)
Abnormal waist circumference 212 (39)
Abnormal waist/hip ratio 301 (56)
Body mass index distribution, kg/m2
18.5 21 (4)
18.6–22.5 127 (24)
22.6–25.0 139 (26)
25.1–30.0 186 (35)
30 64 (12)ata are n (%), mean  SD, median (interquartile range), or percent frequency, as appropriate.rognostic value of waist circumference, WHR, and
MI. During the follow-up period (average 29 months;
ange 1 to 47 months), 182 patients died, 113 of CV causes.
n unadjusted Cox regression analyses, waist (Table 2) and
ip circumferences were unrelated to all-cause and CV
ortality. WHR was a direct predictor of all-cause mortal-
ty, and a 0.1 increase in this ratio was associated with a 25%
ncrease in the risk of all-cause death (HR: 1.25; 95% CI:
.08 to 1.46; p 0.003). In contrast, in unadjusted analyses,
MI was an inverse predictor of both all-cause and CV
ortality (Table 2).
In Cox models adjusting for BMI, hip circumference
emained unrelated to death. However, this adjustment
ubstantially improved the prediction power of waist cir-
umference for all-cause (HR [10-cm increase]: 1.49; 95%
I: 1.26 to 1.77; p 0.001) and CV mortality (HR [10-cm
ncrease]: 1.55; 95% CI: 1.25 to 1.93; p  0.001). Indeed,
he relationship between waist circumference and the inci-
ence rate of all-cause and CV mortality was closely
ependent on BMI categories (above and below the median
alue), the incidence rate of overall and CV death being
aximal in patients with relatively lower BMI (less than
edian) and higher waist circumferences (at least median)
nd minimal in patients with higher BMI (at least median)
nd small waist circumferences (less than median) (Fig. 2).
udy Population
ics of the Study Population
n (n  227) Men (n  310) p Value (Women vs. Men)
4 15 62 14 0.06
(20–106) 48 (19–92) 0.67
(0.1) 59 (19) 0.001
(15) 53 (17) 0.45
(26) 87 (28) 0.57
.6 5.4 24.8 3.6 0.09
0 0.10 0.96 0.09 0.001
.5 14.1 94.2 12.6 0.02
.4 12.6 98.5 10.4 0.005
5 24 138 21 0.21
4 13 76 11 0.02
1 18 62 16 0.81
5 14 75 15 0.67
9 49 150 39 0.001
(99–231) 134 (87–200) 0.01
6 18 44 22 0.20
1 2 11 2 0.23
.7 2.7 5.9 2.8 0.48
(1.8–11.7) 5.2 (2.3–11.6) 0.11
(60) 75 (24) 0.001
(75) 130 (42) 0.001
(5) 9 (3)
(25) 71 (23) 0.89
(24) 85 (27)
(30) 119 (38)
(17) 26 (8)e St
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Abdominal Obesity in ESRD April 14, 2009:1265–72hese analyses indicate that adjustment for BMI is relevant
o capture the risk of all-cause and CV death portended by
aist circumference and suggest that BMI is a suppressor
ariable for the relationship between waist circumference
nd death risk in patients with ESRD. The prognostic
ower of waist circumference for all-cause and CV mortality
as modestly influenced by the inclusion of CV comorbidi-
ies and a series of traditional and emerging risk factors
Table 2), and the predictive value of this indicator did not
aterially change forcing into the models the remaining risk
actors listed in Table 1 (data not shown). In multiple Cox
egression models, WHR was related to all-cause mortality
HR [0.1 increase in WHR]: 1.24; 95% CI: 1.06 to 1.46;
 0.009) and related (p  0.07) to CV mortality (HR [0.1
ncrease in WHR]: 1.21; 95% CI: 0.98 to 1.50). No interaction
as found between waist circumference and BMI with sex and
he remaining risk factors listed in Table 2.
iscussion
n this cohort study in patients with ESRD, a large waist
ircumference was directly associated with an increased risk
f all-cause and CV mortality, whereas BMI was once again
onfirmed as an inverse predictor of these outcomes. After
tatistical adjustment, a 10-cm larger waist circumference
emained associated with a 26% risk excess for death and
8% risk excess for CV death. Because of the opposing
ssociations of waist circumference and BMI with death,
atients with ESRD with large waist circumferences and
ow BMI were at the highest risk of overall and CV mortality,
hereas the probability of death appeared to be minimal in
atients with high BMI but small waist circumferences.
In 2002, the prevalence of obesity in the U.S. Renal Data
ystem was 29%, and the forecasted prevalence for 2007 was
5% (1). Like other European countries, in our cohort, the
roportion of obese patients on dialysis (12%) was less than
n the U.S., which mirrors differences in the general
opulation (1,25). BMI is strongly related to body fat in the
eneral population (26), and it is applied worldwide to
efine the whole range of alterations in nutritional status,
rom malnutrition to extreme obesity (21). Studies in ESRD
ssociating high BMI with reduced death risk and vice versa
bound (27). Even though there are biologic reasons why a
igh BMI may be a protective factor in patients with ESRD
28), the importance of associating measures of lean body
ass or protein-energy nutrition with refining the prognos-
ic implication of a high BMI is well recognized. In
verweight patients, a relatively higher urinary creatinine
denoting a higher muscle mass) predicts a lower risk of
eath (13). Overweight patients with evidence of protein
nergy wasting (as assessed by the subjective global index of
utrition) manifest increased death risk in comparison with
hose with the same BMI without protein energy wasting
obese sarcopenia) (14). It should be noted that the rela-
ionship between global fat mass as measured by dual energy40302010
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April 14, 2009:1265–72 Abdominal Obesity in ESRDality is very similar to that between BMI and the same
linical outcome. In fact, global fat mass was inversely
ssociated with mortality in both American (29) and Japa-
ese (30) patients on dialysis. Furthermore, in female
apanese patients on dialysis, a decrease in global fat mass
as associated with a worse prognosis (31). These findings
cho observations in the general population showing a
-shaped association between global fat mass and mortality
n a middle-aged Danish population (32) and an inverse one
n elderly women in another community-based study in
weden (33).
Although most of the progress realized to date on the
nderstanding of the negative influence of excess body fat
n health has been achieved through studies based on BMI
26), evidence is emerging that BMI is an imperfect metric
or obesity (34). Waist circumference and WHR appear to
e better indicators of this disease than BMI (15,35,36). An
nternational group of experts gathered by the World
ealth Organization formally recommends measurement of
aist circumference and WHR as valid instruments to
stimate the health burden posed by the obesity epidemic
ultivariate Cox Models of All-Cause and Cardiovascular Mortality
Table 2 Multivariate Cox Models of All-Cause and Cardiovascu
Variables (Units of Increase) Unadjusted Adjusted
All-Cau
Waist circumference (10 cm) 1.08 (0.96–1.21)
p value 0.20
Body mass index (1 kg/m2) 0.95 (0.92–0.99)
p value 0.006
Cardiovascular comorbidities (yes/no)
p value
Age (1 yr)
p value
Diabetes (yes/no)
p value
Dialysis vintage (10 months)
p value
Hemoglobin (1 g/dl)
p value
C-reactive protein (5 mg/l)
p value
Cardiovas
Waist circumference (10 cm) 1.09 (0.94–1.27)
p value 0.24
Body mass index (1 kg/m2) 0.95 (0.91–0.99)
p value 0.03
Cardiovascular comorbidities (yes/no)
p value
Age (1 yr)
p value
Diabetes (yes/no)
p value
Calcium  phosphate (1 mg2/dl2)
p value
ata are expressed as hazard ratios (95% confidence intervals) and p values.37), and these measurements are incorporated in the Adult oreatment Panel III guidelines (38). These considerations
ay extend to the CKD population because recent studies
ocumented that waist circumference is strongly related to
isceral fat in these patients (39). To our knowledge, there
s no study measuring waist circumference and WHR and
elating these metrics to clinical outcomes in patients with
SRD. In this study, we observed that, independent of
ther risk factors, waist circumference is directly rather than
nversely associated with overall and CV death. These
ndings were robust and evident across all BMI strata.
imultaneous consideration of waist and hip circumferences
s deemed important because a larger hip circumference at
ny given waist circumference may confer protection against
oronary heart disease (17,40), a phenomenon that may
nderlie dissimilar metabolic effects of visceral and periph-
ral fat (41). Although we found no association between hip
ircumference and death in patients with ESRD, WHR was
trongly associated with death, indicating that visceral fat in
his population denotes a high-risk condition when scaled
o peripheral fat.
Our results are relevant to the current debate on whether
ortality
rdiovascular Comorbidities Fully Adjusted (Reverse Stepwise Analysis)
rtality
8 (1.25–1.76) 1.23 (1.02–1.47)
0.001 0.03
7 (0.83–0.92) 0.89 (0.84–0.94)
0.001 0.001
8 (1.17–2.14) 1.31 (0.97–1.78)
0.003 0.08
1.06 (1.04–1.08)
0.001
2.73 (1.91–3.91)
0.001
1.03 (1.01–1.05)
0.02
0.90 (0.81–0.99)
0.03
1.07 (1.03–1.11)
0.001
Mortality
3 (1.23–1.91) 1.37 (1.09–1.73)
0.001 0.006
7 (0.81–0.93) 0.86 (0.80–0.92)
0.001 0.001
8 (1.43–3.02) 1.71 (1.17–2.49)
0.001 0.005
1.07 (1.05–1.09)
0.001
2.88 (1.87–4.41)
0.001
1.01 (1.00–1.03)
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Abdominal Obesity in ESRD April 14, 2009:1265–72SRD (28,42). Visceral fat produces a variety of factors that
ay impinge upon erythropoiesis, the immune response to
nfectious agents, and the CV and nervous systems. Truncal
at mass is associated with inflammation in ESRD (43).
hus, adiponectin, a CV-protective factor with pleiotropic
ffects, is reduced in the obese; although the issue remains
ontroversial (44), adiponectin levels are inversely related
ith CV events in patients with ESRD (45). Leptin, a
eptide implicated in insulin resistance, sympathetic over-
ctivity, and hypertension in the obese, is increased in
atients with ESRD and predicts adverse CV outcomes in
verweight and obese patients with ESRD (46). Further-
ore, visceral fat is currently seen as an organ with multiple
irect and indirect connections with endocrine, nervous,
nd CV systems, with a relevant role in the generation and
odulation of systemic inflammation. Evidence exists that
isceral fat may have a proinflammatory role in CKD (47)
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Figure 2 Relationship Between All-Cause and CV Death and
Waist Circumference and Body Mass Index
Data are crude (unadjusted) incidence rates and 95% confidence intervals.
Patients are divided into 4 groups according to the median value of waist cir-
cumference and body mass index. CV  cardiovascular.nd ESRD (48). In this regard, it is noteworthy that the Vredictive power of waist circumference and WHR was
argely independent of inflammation as measured by high-
ensitivity CRP. CRP is a penthraxin produced in the liver
nder stimulation of cytokines synthesized in fat tissue such
s interleukin-1-beta, interleukin-6, and tumor necrosis
actor-alpha. Circulating CRP is more dependent on insulin
esistance rather than on waist circumference (49). Our
nding that waist circumference predicts death indepen-
ently of CRP suggests that this marker may be an
mperfect indicator of the inflammation burden associated
ith abdominal obesity in patients with ESRD or that
echanism(s) other than inflammation contribute to the
igh risk of fat excess in this population.
tudy limitations. Although the demographic and anthro-
ometric characteristics of our cohort and the mortality rate
ere similar to the corresponding average values (50)
escribed in the national Italian registry, the present study
as based on a relatively small cohort of white patients and
herefore our findings need to be confirmed in larger studies
nd other ethnicities. The results of our study just apply to
he ESRD population and may not be valid in cohorts of
atients with coronary heart disease and/or heart failure,
igher BMI, and milder forms of renal insufficiency. Sec-
nd, although we standardized WHR measurements ac-
ording to World Health Organization recommendations,
here may be substantial absolute errors in measuring waist
nd hip circumferences, which are greater in women than
en (51) and greater than in measuring BMI. Therefore,
ecause of the regression to the mean phenomenon, we may
ave underestimated the effect of waist circumference and
HR on clinical outcomes. Third, our study does not
rovide any information on interventions that result in
eight loss or reductions in waist circumference.
onclusions
t all BMI categories, from underweight to frank obesity,
aist circumference is a strong, direct, independent predic-
or of all-cause and CV death. Similarly, WHR is linearly
elated in a direct fashion with adverse clinical outcomes.
edefinition of nutritional status by combining metrics of
bdominal obesity and BMI may refine prognosis in the
SRD population. Further studies will clarify the mediators
n visceral fat tissue that determine the high risk of a large
aist circumference in ESRD.
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